II. Epidemiology
- See Leishmaniasis
III. Pathophysiology
- See Leishmaniasis
- Incubation: 2-8 weeks
IV. Types
- See Visceral Leishmaniasis
- Simple Cutaneous Leishmaniasis (Old World Cutaneous Leishmaniasis)
- Acquired in Africa, Asia and Europe
- Causes
- Leishmania tropica (urban)
- Leishmania major (desert)
- Leishmania aethiopica
- Description
- Incubation 2-24 months
- Single Papule forms at sandfly bite site on face or leg
- Papule necroses and forms a single ulcer ("oriental sore")
- Leishmania can be seen in ulcer bed scrapings under microscopy
- Ulcer heals over the course of the year
- Hypopigmented scar remains at bite site
- Cell mediated Immunity limits infection to localized skin lesion
- Future delayed Hypersensitivity to Leishmania
- Leishmanin Skin Test
- Intradermal injection of LeishmaniaAntigen results in PPD-like reaction at 48-72 hours
- Mucocutaneous Leishmaniasis (New World Leishmaniasis)
- Acquired in latin america
- Causes
- Leishmania leishmania (e.g. mexicana, chagasi)
- Leishmania viannia (e.g. panamensis, braziliensis)
- Begins with Nodules or Skin Ulcers at sandfly bite (as with simple Cutaneous Leishmaniasis)
- Lesions are typically on the hands, ear or face
- Mucous membrane ulcers form on mouth and nose, months to years after Skin Ulcer heals
- Mucosal lesions are destructive (esp. nose, Palate)
- Lesion scrapings demonstrate Leishmania under microscopy
- Chronic infections in untreated patients leads to erosions of the nasal septum, Palate and lips
- Lesions develop over decades in untreated patients
- Complications (esp. secondary Bacterial Infections) may be lethal
- Diffuse Cutaneous Leishmaniasis
- Less common than other forms of Leishmaniasis
- Associated with specific Leishmania species (e.g. L. amazonensis, L. mexicana, L. aethiopica)
- Most severe cases reported in Brazil, Ethiopia, Sudan, South Sudan, India, and Bangladesh
- Chronic form of Cutaneous Leishmaniasis in Immunocompromised patients
- Nodular skin lesion forms at sandfly bite but does not ulcerate
- Diffuse skin Nodules develop over time, distant from the initial bite site
- Predisposition for perinasal lesions
- Infection persists for decades in untreated patients
- Less common than other forms of Leishmaniasis
V. Signs
- See Nodular Lymphangitis
- Primary Lesion 2 to 8 weeks after sandfly bite
- Secondary Lesions
- Nodular Lymphangitis may occur
- Ascending Nodules along lymph chain
- Systemic signs (rare in cutaneous disease)
- See Visceral Leishmaniasis for systemic disease
- Occurs in immunosuppressed patients (e.g. HIV)
- Fever
- Regional adenopathy
- Scarring
- Skin lesions spontaneously resolve in months
- Healing delayed in some forms (e.g. L. brazilensis)
- Round depressed scar forms on healing
VI. Differential Diagnosis
- Skin lesions: Nodular Lymphangitis
- Mucosal lesions
- See Oral Ulcer
VII. Diagnosis
- Skin scraping (5 slides)
- Remove crust before scraping
- Scrape lesion margin and central ulcer
- Punch Biopsy ulcer edge
- Needle aspirate
- Inject saline into border via skin
- Aspirate while inserting and withdrawing needle
- Culture aspirate on Nicolle-Novy-MacNeal media
VIII. Management
- See Visceral Leishmaniasis for systemic Leishmaniasis
- Mild Cutaneous Leishmaniasis
- Treatment duration: 20 days
- Apply Local Heat to area for 2-3 hours per day
- Many lesions heal with observation alone
- Paromomycin ointment twice daily on days 1-10 and 20-30
- Apply in two cycles of 10 days each with 10 intervening days between
- Intralesional Meglumine antimonate (Glucantime)
- Inject undiluted solution intralesionally
- Inject up to 20 mg/kg total or 850 mg of antimony component weekly for 5-10 weeks
- May be combined with Cryotherapy
- Other local therapy
- Cryotherapy (up to 3 times)
- Laser Therapy
- Complex or Diffuse Cutaneous Leishmaniasis (including all cases of Leishmania braziliensis)
- Meglumine Antimoniate (Glucantime)
- Dilute intravenous doses in 50 ml D5W or NS prior to administration and deliver over >=20 minutes
- Inject 20 mg/kg/day up to 850 mg (of antimony component) IV or IM daily for 20 days (28 days for mucosal)
- Liposomal Amphotericin B
- Dose 3 mg/kg IV daily for 7 days
- Dosing regimen is modified for L. braziliensis (see other references)
- Alternative agents (see other references for dosing)
- Meglumine Antimoniate (Glucantime)
- Mucosal Leishmaniasis
- Liposomal Amphotericin B
- See other resources for dosing regiments
- Meglumine Antimoniate (Glucantime)
- See above for dosing regimen
- Mucosal Leishmaniasis treatment duration for 28 days
- Alternative agents
- Miltefosine may be effective in some cases
- Liposomal Amphotericin B
IX. Prevention
X. References
- Freedman (2025) Sanford Guide, accessed 7/13/2025 on IOS
- Gladwin, Trattler and Mahan (2014) Clinical Microbiology, Medmaster, Fl, p. 348-9
- de Vries (2022) Am J Clin Dermatol 23(6):823-40 +PMID: 36103050 [PubMed]
- Herwaldt (1999) Lancet 354:1191-9 [PubMed]
- Pearson (1996) Clin Infect Dis 22:1-13 [PubMed]
- Tobin (2001) Am Fam Physician 63(2):326-32 [PubMed]
- Markle (2004) Am Fam Physician 69(6):455-60 [PubMed]